(RTTNews) - Bayer (BAYZF.PK, BAYRY.PK, BYR.L), a German pharmaceutical and life sciences major, announced that the European Commission has granted a label extension in the European Union for Eylea ...

So a very meaningful expansion opportunity for EYLEA HD and potentially could be the only product approved with every 8-week dosing. And lastly, every 4-week dosing is another label enhancement we ...

Eylea HD should also earn some label expansions. Meanwhile, Regeneron's other growth driver is Dupixent, a medicine for eczema. It shares the rights to Dupixent with Sanofi.

Our Top 5 Analyst Questions Regeneron’s Q1 Earnings Call Tyler Van Buren (TD Cowen) asked about the timeline and specifics behind the EYLEA HD pre-filled syringe regulatory delay. CEO Leonard ...

Introduction and Overview Regeneron has experienced a turbulent period, with its stock price declining significantly from its peak in August 2024. The company’s flagship product, Eylea, has faced ...

Moderna has a deep pipeline of promising mRNA candidates that stand to boost business. Regeneron is looking at label expansions for its main product as well as clinical progress elsewhere. Here ...

Alvotech is also developing AVT29, a proposed biosimilar to Eylea® HD, a higher dose (aflibercept 8 mg) aflibercept. Advanz has licensed the distribution rights from Alvotech for both biosimilar ...

In January 2024 Alvotech announced positive top-line results from a confirmatory clinical study with AVT06 (AVT06-GL-C01) comparing the efficacy, safety, and immunogenicity of the proposed biosimilar ...

Eylea HD earned $1.2bn of revenues of in 2024, in its first full year on the market.